Role of type 1 angiotensin-receptor blockers in the correction of arterial hypertension in fertile-age women
https://doi.org/10.18705/1607-419X-2003-9-5-164-166
Abstract
The antihypertensive effect of diovan in the medical correction of arterial hypertension (AH) was tested in fertile-age women. The specific features of the agent were studied in relation to the gene polymorphism of angiotensin-converting enzyme (ACE) and antagonists of type 1 receptors to angiolensin-ll receptor blockers (ATR1). The use of diovan, 80 mg daily, to correct AH in fertile-age females was found to promote the normalization of the daily blood pressure profile, the improvement of the lipid spectrum, and cardioprotection. There was an association of the efficacy of diovan and the structural status of ACE and ATR1 genes. The maximum efficacy of the drug may be expected in patients with DD genotype (ACE gene) and AC genotype (ATP1 gene).
About the Authors
S. A. Turdialiyeva
Военно-медицинская академия им. С.М. Кирова
Russian Federation
Russian Federation
R. M. Linchak
Военно-медицинская академия им. С.М. Кирова
Russian Federation
Russian Federation
A. S. Svistov
Военно-медицинская академия им. С.М. Кирова
Russian Federation
Russian Federation
S. A. Boitsov
ФГБУ «ГНИЦ ПМ» Минздравсоцразвития РФ; ФГБУ «Государственный научно-исследовательский центр профилактической медицины» МЗиСР
Russian Federation
Russian Federation
M. A. Karpenko
ФГБУ «Федеральный Центр сердца, крови и эдокринологии им. В.А. Алмазова» Минздрава России
Russian Federation
Russian Federation
References
1. Cifkova R., Peleska J., Hradec J., Rosolova H., Pinterova E., Zeman K., Oddou Strock P., Thirlwell J., Botteri F. Valsartan and atenolol in patients with severe essential hypertension. J Hum Hypertens. 1998 Aug;12 (8): 563-7.
2. Holwerda N.J., Fogari R., Angeli P., Porcellati C., Herenq C., Oddou-Stock P., Heath R., Bodin F. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril. J Hypertens. 1996 Sep;14 (9): 1147-51.
3. Hegner G., Faust G., Freitag F., Meilenbrock S., Sullivan J., Bodin F. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared to hydrochlorothiazide. Eur J Clin Pharmacol. 1997; 52 (3): 173-7.
4. Viberti G., Wheeldon N.M., MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation. 2002 Aug 6; 106 (6): 672-8.
5. Pool J., Oparil S., Hedner T. et al. Valsartan is an effective antihypertensive in both women and men: an integrated analysis. Am J Hypertens 2000; 13: 278.
6. Bremner A.D., Mehring G.H., Mielenbrock S. Long-term systemic tolerability of valsartan compared with lisinopril in elderly hypertensive patients. Adv Ther 1997: 14: 245-53.
7. Patet JKV, Leaback R. on behalf of the POSATIV investigators. Patients of Soutbern Asian descent treated with valsartan (POSATIV) study. Br J Cardiot 2002; 9: 351-4.
8. Schmieder R.E., Martus P., Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies. JAMA. 1996 May 15; 275 (19): 1507-13.
9. Natbantgil S., Yilmaz H., Gurun C et al. Effects of valsartan and enalapril on regression of left ventricular hypertrophy in patients with mild to moderate hypertension: a randomized, double-blind study. GurrTher Res Clin E 200; 61: 331-8.
10. Parving H.H., Legnert H., Brocher-Mortensen J., Gomis R., Andersen S., Arner P., Irbesartan in Patients with Type 2 Diabetes and Microalbuminuris Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001 Sep 20; 345 (12): 870-8.
11. Lewis E.J., Hunsicker L.G., Clarke W.R., Berl T., Pohl M.A., Lewis J.B., Ritz E., Atkins R.C., Rohde R., Raz I., Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001 Sep 20; 345 (12): 851-60.
12. Fogari R., Preti P., Derosa G., Marasi G., Zoppi A., Rinaldi A., Mugellini A. Effect of antihypertensive treatment with valsartan or atenolol on sexual activity and plasma testosterone in hypertensive men. Eur J Clin Pharmacol. 2002 Jun; 58 (3): 177-80. Epub 2002 May 1.
13. Диденко В.А., Симонова Д.В. Влияние блокаторов рецепторов ангиотензина II лозартана на метаболические показатели и морфофункциональное состояние миокарда в процессе терапии больных гипертонической болезнью. Клин. медицина 1998; 9: 33-7.
14. Dahlof B., Devereux R.B., Kjeldsen S.E., Julius S., Beevers G., de Faire U., Fyhrquist F., Ibsen H., Kristiansson K., Lederballe-Pedersen O., Lindholm L.H., Nieminen M.S., Omvik P., Oparil S., Wedel H., LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002 Mar 23; 359 (9311): 995-1003.
15. Fogari R., Zoppi A., Mugellini A. et al. Comparative effect of losartan and valsartan in mild-to-moderate hypertension: results of 24-hour ambulatory blood pressure monitoring. Curr. Ther Res Clin E 1999: 60: 195-206.
16. Cannella G., Paoletti E., Barocci S., Massarino F., Delfino R., Ravera G., Di Maio G., Nocera A., Patrone P., Rolla D. Angiotensin-converting enzyme gene polymorphism and reversibility of uremic left ventricular hypertrophy following long-term antihypertensive therapy. Kidney Int. 1998 Aug; 54 (2): 618-26.
17. Kohno M., Yokokawa K., Minami M., Kano H., Yasunari K., Hanehira T., Yoshikawa J. Association between angiotensin-converting enzyme gene polymorphisms and regression of left ventricular hypertrophy in patients treated with angiotensin-converting enzyme inhibitors. Am J Med. 1999 May; 106 (5): 544-9.
18. Cheung R., Lewanczuk R.Z., Rodger N.W., Huff M.W., Oddou-Stock P., Botteri F., Pecher E., Muirhead N. The effect of valsartan and captopril on lipid parameters in patients with type II diabetes mellitus and nephropathy. Int J Clin Pract. 1999 Dec; 53 (8): 584-92.
19. Cianflone K.M., Yasruel Z., Rodrigues M.A., Vas D., Sniderman A.D. Regulation of apoB secretion from HepG2 cells: evidence for a critical role for cholesteryl ester synthesis in the response to a fatty acid challenge. J Lipid Res. 1990 Nov; 31 (11): 2045-55.
20. Schafer F.J., Levy R.I. Pathogenesis and management of lipoprotein disorders. N Engi J Med 1985; 312: 1300-10.
21. Thompson G.R., Naoumova R.P., Watts G.R. Role of cholesterol in regulating apolipoprotein B secretion by the liver. J Lipid Res. 1996 Mar; 37 (3): 439-47.
22. Litwin S.E., Grossman W. Diastolic dysfunction as a cause of heart failure. J Am Coll Cardiol. 1993 Oct; 22 (4 Suppl A): 49A-55A.
Review
For citations:
Turdialiyeva S.A., Linchak R.M., Svistov A.S., Boitsov S.A., Karpenko M.A. Role of type 1 angiotensin-receptor blockers in the correction of arterial hypertension in fertile-age women. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2003;9(5):164-166. (In Russ.) https://doi.org/10.18705/1607-419X-2003-9-5-164-166
Views:
804
Email this article 